Brief · Use case · Regulatory
External Control Evidence Assessment.
LiveAssessmentJudge whether a single-arm trial with an external control can support accelerated approval for a rare pediatric therapy, and where that position is weakest.
External Control Evidence Assessment is a ready-made use case for Regulatory. It ships under the Assessment template.
For regulatory and clinical development leads weighing an evidence package. You get a stated position and confidence, the supporting findings graded for certainty, the strongest objection restated fairly and answered, and the conditions that would overturn it. Claims are cited or marked as gaps.
Add it to your library to reuse from New → From template. Edit the saved copy in your library on the service form.
The decision
How well supported is the position that a single-arm trial with an external control arm is sufficient to support accelerated approval for a rare pediatric disease therapy?
What the assessment examines
The position has three parts that can fail separately: the design, the external control, and the route to accelerated approval. The assessment grades the evidence for each.
| Part of the position | What the assessment examines | Where it looks |
|---|---|---|
| The single-arm design | EU regulators treat randomized controlled evidence as the standard for confirmatory efficacy, and a sponsor who relies on a single-arm trial must justify that departure.1 | The EMA reflection paper on single-arm trials as pivotal evidence (final, first published 16 September 2024). |
| The external control | Whether the outside group is comparable to the treated group on the factors that drive the outcome, and how bias is handled. FDA’s draft guidance on externally controlled trials covers design, analysis and threats to validity.2 | FDA’s draft guidance of February 2023 (docket FDA-2022-D-2983). |
| The rare disease setting | What FDA says about development programs for rare diseases, where small populations limit what a trial can show.3 | FDA’s final guidance, Rare Diseases: Considerations for the Development of Drugs and Biological Products (December 2023). |
| The accelerated approval route | FDA’s December 2024 draft says that, except in limited circumstances, it intends to require that the confirmatory trial be underway at approval.4 | FDA’s draft guidance on accelerated approval and the companion draft on whether a confirmatory trial is underway. |
What the assessment does
Each part is graded on its own. The design, the control and the route can each be strong or weak, and a weak link sets the strength of the whole. The assessment grades each and says which link limits the position.
The objection from bias. Without randomization, an external control cannot rule out systematic differences between the groups, and FDA’s draft guidance says external controls are usually reserved for specific circumstances. The assessment restates the objection fairly and answers it from the data and from what the guidance lets a sponsor show.1,2
The confirmatory trial is part of the position. Under FDA’s December 2024 draft, a position that depends on accelerated approval depends on a confirmatory trial that is underway. The assessment treats the plan for that trial as a finding, and says the draft is not final.4
FDA and EMA differ in standing. The FDA documents are drafts with non-binding recommendations, apart from the final rare disease guidance. The EMA paper is a final reflection paper. The assessment labels each document with its status.1,2,3,4
Recommended length
Comprehensive
The position will be challenged by people who hold another view. Comprehensive adds the alternatives considered and the reasoning behind the support, which is what a challenger asks for.
You can pick another length on the form. The other two stay available.
Assumptions the assessment checks
The assessment states the assumptions the position rests on and says which one would hurt most if it failed. Examples for this position:
- The external control group matches the treated group on baseline severity and standard of care.
- A confirmatory trial is feasible and will be underway at the time of the decision.
- The regulator will accept the endpoint as reasonably likely to predict clinical benefit.
Standards, guidance and sources
Design and control
Rare disease and accelerated approval
The decision practice behind the memo itself is on the template page.
What gets flagged
Any statement of regulatory acceptance that rests on a draft, any comparability claim about the external control that has no data behind it, and the confirmatory trial plan if none is on the record.
What arrives
- The position
- The basis
- Why the evidence supports it
- The strongest objection, answered
- Other views considered
- Where it is weak
What it will not do
It does not recommend an action. A Decision Memo takes the assessment as its starting point.
It does not predict whether FDA or EMA will accept the file.
It does not recommend an action. An assessment says how well a position is supported; a Decision Memo recommends what to do.
Certainty ratings are analyst judgment from an AI specialist, not measurements, and the reason for each is on the page so you can disagree with it.
It does not settle a question the evidence leaves open. Where the evidence is thin, the assessment says so and says what would settle it.
References
- [1] European Medicines Agency. Reflection paper on establishing efficacy based on single-arm trials submitted as pivotal evidence in a marketing authorisation, EMA/CHMP/430688/2024. First published 16 September 2024. Read on 9 October 2026: final; randomized evidence remains the standard.
- [2] U.S. Food and Drug Administration. Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products. Draft guidance, February 2023. Docket FDA-2022-D-2983. Read on 9 October 2026: draft, non-binding.
- [3] U.S. Food and Drug Administration. Rare Diseases: Considerations for the Development of Drugs and Biological Products. Final guidance, December 2023. Status and docket as given in FDA listings and search excerpts; the guidance text was not read.
- [4] U.S. Food and Drug Administration. Expedited Program for Serious Conditions: Accelerated Approval of Drugs and Biologics (draft, December 2024); Accelerated Approval and Considerations for Determining Whether a Confirmatory Trial is Underway (draft, January 2025, docket FDA-2024-D-3334). Both are drafts as of the sources found; check whether either has been finalized.
Links checked 9 October 2026
These are the sources the template drew on. None of their authors or issuers has reviewed it.
About the Brief service
A Brief is a written answer from one specialist, at the depth you asked for. It arrives with its sources, and it closes by saying plainly what would change the conclusion. Nothing is hidden behind a summary, and anything the expert could not source is marked as a gap rather than filled in.
To edit a saved template, open New → Brief → From template, or the library rail on the service form.